Common questions researchers ask about AOD-9604 — laboratory context only.
What part of growth hormone does AOD-9604 correspond to?
It reproduces a modified 15-residue stretch drawn from the C-terminal end of human growth hormone, with an added N-terminal tyrosine. The rationale for isolating just this fragment is covered in its chemistry article.
Does AOD-9604 trigger the same response as full-length growth hormone?
No — a defining feature explored in its mechanism of action is that it is not expected to activate the growth-hormone receptor the way intact GH does, which is why it is studied as a narrower metabolic probe rather than a hormone substitute.
How does it differ from GH secretagogues like sermorelin or ipamorelin?
Secretagogues such as sermorelin and ipamorelin act upstream to trigger endogenous GH release. AOD-9604 works downstream of that step, engaging lipid-metabolism readouts directly in model systems without relying on a release event.
What model systems is it studied in?
Primarily cultured adipocyte preparations and rodent models, summarized in its preclinical research article — always framed as controlled-model observation, not translational outcome.
How is AOD-9604 supplied and handled?
As a lyophilized powder requiring cold, dark storage before reconstitution; see reconstitution and storage for general laboratory handling.
What documentation should accompany a research lot?
A lot-specific certificate of analysis confirming sequence identity and purity — see how to read a CoA.
Product page: AOD-9604 research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.